In Part II of our discussion with DARA Biosciences (NASDAQ: DARA) CEO and Chief Medical Officer Dr. David Drutz, we look into key catalysts for the specialty pharmaceutical company. Dr. Drutz discusses the medical need for the oral-liquid tamoxifen, Soltamox, licensed to DARA by UK-based Rosemont Pharmaceuticals — as well as the market opportunity in developing oncology services.
DARA Biosciences has created some buzz as of late, landing on several ‘watch lists’ after the company’s exclusive licensing of three market-ready products for distribution in the United States. CEO/Chief Medical Officer Dr. David Drutz and COO Chris Clement conducted a two-part interview with OneMedRadio discussing developmental milestones and key catalysts for Q4-2012 and 2013.
OneMedPlace introduces a new series, “The Briefing Room”, capturing the most important developments in microcap life sciences indexes. This week, we focus on three interesting developments in oncology, and a special bonus!
At OneMedPlace, our goal is to be your eyes and ears to the biotech and life sciences sector: putting into perspective what we’ve seen so far, and providing you with snapshots of and what’s upcoming.
IMMUNE Pharmaceuticals is an Israeli and US based emerging leader in the development of antibody therapeutics in cancer and inflammation. IMMUNE has multiple drug candidates based on proprietary cytotoxic formulations, linkers and monoclonal antibodies.
Apricus Bio VP Edward Cox discusses the future of drug delivery technology in the rapidly expanding world of personalized medicine.
EpiCept Corporation recently announced operating and financial results for the year 2010, and provided an update on its key business initiatives.
Over 500,000 people will die from cancer in the United States this year. There are many companies developing diagnostics for early detection and advanced therapies to address the various types of cancer.
The New York Society of Security Analysts, a leading forum for the investment community, recently announced the presenter list for its 14th Annual Biotech and Specialty Pharma Conference.
The growing global incidence of breast cancer has led to an increased demand for molecular diagnostics tests that aid in diagnosing breast cancer.
Copyright © 2025 | WordPress Theme by MH Themes